Christopher Richard Anzalone, Chief Executive Officer at ARROWHEAD PHARMACEUTICALS, INC. (ARWR), sold 19,904 shares at $30.74 ($617K) on 2024-01-02, disclosed to the SEC on 2024-01-04.
Scheduled sale ($617k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.74 | 4,634 | $142K | 23.1% |
| 2 | $30.74 | 4,634 | $142K | 23.1% |
| 3 | $31.25 | 5,318 | $166K | 26.9% |
| 4 | $31.25 | 5,318 | $166K | 26.9% |
| Total | $31.01 avg | 19,904 | $617K | 100% |
| Filing → |
| ARWR | SELL | 2025-12-23 | $3.5M | — | Filing → |
| ARWR | SELL | 2025-12-19 | $10.9M | — | Filing → |
| ARWR | SELL | 2025-12-16 | $24.6M | — | Filing → |